REGN — REGENERON PHARMACEUTICALS, INC. catalysts

Name: Bio Catalyst Calendar — source-anchored biotech/pharma catalyst dates
Creator: Bio Catalyst Calendar
License: https://www.usa.gov/government-works

6 verified catalyst event(s) for REGENERON PHARMACEUTICALS, INC. (ticker REGN). Each is linked to its official source. Verified as of 2026-11-05.

Next verified catalyst

2026-11-13 — A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemipli · official source ↗

Upcoming

Date	Event	Company	Drug	Official source & verification
2026-11-13 in 8d ESTIMATED	READOUT A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination Wi Phase 1/2 · Advanced Solid Tumors	REGN REGENERON PHARMACEUTICALS, I	REGN7075, Cemiplimab, Platinum-based dou	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-13 in 8d ESTIMATED	READOUT Study of Olatorepatide in Adult Participants Living With Overweight or Obesity i Phase 2 · Overweight or Obesity	REGN REGENERON PHARMACEUTICALS, I	Olatorepatide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-03 in 28d ESTIMATED	READOUT A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Phase 2 · Non-Transfusion Dependent Beta-Thalassemia (NTDT)	REGN REGENERON PHARMACEUTICALS, I	REGN7999	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-29 in 2mo ESTIMATED	READOUT A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult P Phase 2 · Hypercholesterolemia	REGN REGENERON PHARMACEUTICALS, I	Alirocumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2027-02-09 in 3mo ESTIMATED	READOUT Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Antic Phase 2 · Atrial Fibrillation (AF)	REGN REGENERON PHARMACEUTICALS, I	REGN7508, REGN9933, Apixaban	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2027-02-20 in 4mo ESTIMATED	READOUT REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Phase 3 · Venous Thromboembolism (VTE)	REGN REGENERON PHARMACEUTICALS, I	REGN7508, Apixaban, Enoxaparin	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change